Trump allies call for Senate parliamentarian to be removed. Who is Elizabeth MacDonough?
WASHINGTON - Republican are calling for the Senate's parliamentarian to be fired after she ruled that several Medicaid provisions must be taken out of President Donald Trump's tax, spending and policy bill, spelling trouble for the president and his party as they try to get the legislation signed into law by a self-imposed July 4 deadline.
The chamber's leading rules expert, Elizabeth MacDonough, sided on June 26 against the inclusion of provisions that the GOP wanted to put in the bill aimed at reducing spending on Medicaid by requiring work from able-bodied adults and denying access to non-citizens. That didn't go over well with deficit hawks trying to secure for Trump his biggest legislative win of his second term.
'This is a perfect example of why Americans hate THE SWAMP. Unelected bureaucrats think they know better than U.S. Congressmen who are elected BY THE PEOPLE. Her job is not to push a woke agenda.THE SENATE PARLIAMENTARIAN SHOULD BE FIRED ASAP,' Alabama Republican Sen. Tommy Tuberville wrote on X.
Republican Reps. Greg Steube of Florida, Marjorie Taylor Greene of Georgia and Dan Crenshaw of Texas also called for Senate Majority Leader John Thune to fire MacDonough. 'I don't think it's good strategy to die on every hill, but THIS is a hill we should fight for,' Crenshaw wrote on X.
For now, it appears MacDonough's job is secure: Thune, a South Dakota Republican, told reporters the GOP had no plans to overrule its parliamentarian, let alone fire her. Still, it's not the first time MacDonough has faced partisan pushback in Congress. Democrats have also railed against her decisions when they held the White House.
Who is Elizabeth MacDonough?
MacDonough is the first female parliamentarian of the Senate, a role that then-Majority Leader Harry Reid promoted her to in 2012. The parliamentarian's responsibilities include advising senators and other staff about the chamber's rules and statutes, and managing the process of referring bills to committees, according to the Bipartisan Policy Center.
When Congress aims to pass budget reconciliation bills, such as the one being negotiated in the Senate, the parliamentarian can strike out any provisions that are extraneous and non-budgetary in nature under a process known as 'Byrd Bath,' named after the late-Sen. Robert Byrd, D-West Virginia.
Though MacDonough is rarely one of the most visible figures on Capitol Hill, she can be the most crucial at times. In 2021, for instance, Democrats complained after she ruled that they couldn't include a provision to increase the federal minimum wage to $15 an hour in an economic stimulus bill then-President Joe Biden was pushing in response to the COVID-19 pandemic.
MacDonough also advised Chief Justice John Roberts during both of Trump's Senate impeachment trials, including the one that came in response to rioters storming the U.S. Capitol on Jan. 6, 2021. MacDonough's office was ransacked during the melee and, according to The New York Times, she returned to work days after the attack wearing a hazmat suit.
Asked on June 26 if Trump agreed with the calls from inside the GOP to remove the Senate parliamentarian, White House press secretary Karoline Leavitt replied that she hasn't spoken to Trump about the topic.
'He knows this is part of the process and the inner-workings of the Senate,' Leavitt said. 'He wants to see this bill done. He remains very much engaged in these conversations and in this process with lawmakers in both the Senate and the House side, and the whole White House does as well.'
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
The Hill
23 minutes ago
- The Hill
China hawks skeptical of Trump chip deal
Trump on Monday agreed to allow tech giants Nvidia and AMD to secure export licenses to sell their advanced artificial intelligence (AI) chips in China in exchange for a 15 percent cut of the profits. The White House said Tuesday that more such deals could be on the table. The unusual deal doesn't just raise legal questions. Experts say the U.S. should be wary of turning over American-made technology that could boost its adversary's AI capabilities, at a time when the two countries are fiercely competing for dominance. The security concerns appear to be a two-way street. China urged tech companies there to avoid any purchase of Nvidia's H20 chip, citing security issues. The move once again has Trump at odds with Congress's China hawks, who argue the administration is shortchanging America's national security interests to make a buck. Rep. Raja Krishnamoorthi (Ill.), the top Democrat on the House Select Committee on the Chinese Communist Party, in a statement said the most troubling part of the deal was a contradiction at the heart of the policy. 'The administration cannot simultaneously treat semiconductor exports as both a national security threat and a revenue opportunity,' he said. 'By putting a price on our security concerns, we signal to China and our allies that American national security principles are negotiable for the right fee.' The same panel's GOP chair, Rep. John Moolenaar (Mich.), said there are 'questions about the legal basis' for such a deal. 'Export controls are a frontline defense in protecting our national security, and we should not set a precedent that incentivizes the Government to grant licenses to sell China technology that will enhance its AI capabilities,' he said in a statement.
Axios
23 minutes ago
- Axios
Homelessness climbs in Utah, especially for older adults
Homelessness in Utah is worsening, with sharp increases among older adults and veterans, according to a new state report. The big picture: An increasing share of Utah's senior population, many of whom depend on fixed incomes, is unable to keep up with rising housing costs, according to an annual report released Wednesday by the Utah Office of Homeless Services. By the numbers: The number of people experiencing homelessness in Utah rose 18% from the previous year, per a January point-in-time count. Among Utahns over age 64, homelessness grew by 42%, while veterans saw a 36% jump. Children lacking permanent housing increased by 12%. People encountering chronic homelessness saw a 36% rise. Meanwhile, first-time homelessness experienced a 5% uptick between 2023 and 2024, the report showed. What they're saying: "I am deeply concerned about the trajectory of homelessness in the state of Utah and in our capital city," Salt Lake City Mayor Erin Mendenhall said in response to the newly released figures during a Wednesday news conference outside city hall. Mendenhall lambasted state lawmakers for their "lack of forward momentum" to address the state's homelessness crisis. The other side: In a joint statement, Gov. Spencer Cox, Senate President Stuart Adams, House Speaker Mike Schultz said state leaders have stepped up to help local governments "find real solutions" to curb homelessness. "It's frustrating to continuously take one step forward and two steps back with Salt Lake City," per the statement that urged Mendenhall to "turn down the politics." Zoom out: The state's homeless rate is 13 per 100,000 people — below the 2024 national rate of 23 per 100,000 people, according to the data. Zoom in: The vast majority of people (95%) included in January's count were in shelters, compared with 18% in 2023, a milestone that state leaders attributed to the expansion of winter shelter capacity.
The Hill
23 minutes ago
- The Hill
NIH cancels mRNA vaccine contracts, citing lack of public trust
National Institutes of Health Director Jay Bhattacharya claims the federal government recently cancelled millions of dollars' worth of mRNA research contracts because the general public does not trust the technology. Bhattacharya explained the reason behind the abrupt contract cancellations, first, during an episode of Republican political strategist Steve Bannon's podcast 'War Room' last week and again in an opinion piece recently published in The Washington Post. In the article, Bhattacharya called the mRNA platform a 'promising technology' and acknowledged that it may lead to breakthroughs in treatment for diseases like cancer. 'But as a vaccine intended for broad public use, especially during a public health emergency, the platform has failed a crucial test: earning public trust,' he wrote. 'No matter how elegant the science, a platform that lacks credibility among the people it seeks to protect cannot fulfill its public health mission.' Bhattacharya's explanation for the administration's pivot away from mRNA technology differs from that of his boss, Health and Human Services Secretary Robert F. Kennedy Jr. Kennedy announced last week the agency would wind down its mRNA vaccine development activities under the Biomedical Advanced Research and Development Authority (BARDA) and cancel $500 million worth of contracts related to the technology. He said that mRNA technologies funded during the pandemic failed to meet current scientific standards and that the federal government would shift its focus to whole-virus vaccines and novel platforms. Bhattacharya expressed concern in the article about mRNA vaccines' ability to direct human cells to produce spike proteins to trigger an immune response. He argues the scientific community does not have a clear understanding of where mRNA product stays in the body, for how long, and whether other proteins are created in the process. Scott Hensley, a microbiology professor at the University of Pennsylvania's Perelman School of Medicine, told STAT that these are also issues with vaccines that use live but weakened viruses like the measles, mumps, and rubella vaccine, which federal health agencies have deemed safe and effective. 'This is why we complete human clinical studies before vaccines are widely used in humans,' he told the outlet. 'The mRNA and live attenuated vaccine platforms have both proven to be safe and effective in clinical trials.' He blamed public distrust in mRNA on the Biden administration's COVID-19 vaccine mandates during the pandemic. Bhattacharya expressed concern in the article about mRNA vaccines' ability to direct human cells to produce spike proteins to trigger an immune response. He argues the scientific community does not have a clear understanding of where the mRNA product stays in the body, for how long, and whether other proteins are created in the process. 'Science isn't propaganda,' he wrote. 'It's humility. And when public health officials stopped communicating with humility, we lost much of the public, an absolute necessity for any vaccine platform.'
